The Evidence for Sparsentan-Mediated Inhibition of INa and IK(erg): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor
Sign Up to like & getrecommendations! Published in 2021 at "Biomedicines"
DOI: 10.3390/biomedicines10010086
Abstract: Sparsentan is viewed as a dual antagonist of endothelin type A (ETA) receptor and angiotensin II (AngII) receptor and it could be beneficial in patients with focal segmental glomerulosclerosis. Moreover, it could improve glomerular filtration… read more here.
Keywords: angiotensin; sparsentan; ina; presence ... See more keywords